As the distant #3 in the radiation oncology market, Accuray (ARAY)
already has a tough row to hoe and past issues with product reliability
and present-day concerns about the cost effectiveness of its systems
don't help matters. Even so, it looks like the new CyberKnife M6 and
Tomo H products, coupled with operating cost improvements, are giving
this company another chance at making a real go of it. The stock's
nearly 20% jump since my last update has certainly taken some urgency
out of the relative value call, but the pace of order improvements and
the extent of skepticism about the company still offer arguments for a
long position.
Please follow this link to read more:
Accuray Continues To Turn It Around
No comments:
Post a Comment